E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Bronchiectasis is a condition of the lungs whereby there is inflammation, increased sputum production and recurrent chest infection. This results in a cycle of infection and further damage. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006445 |
E.1.2 | Term | Bronchiectasis |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Research tells us that erythromycin can reduce exacerbation frequency in bronchiectasis by greater than 50% with minimal side-effects. We know that this category of antibiotics (macrolides) can reduce sputum volume and improve quality of life by reducing lung inflammation rather than killing bacteria in a variety of different lung conditions. We also know from our own clinic data that in some patients a 3 month course of erythromycin can improve lung function by a considerable amount. The patients that improve the most have certain changes in the very small airways on their CT scans and have a lot of inflammatory cells in their sputum, called neutrophils. What we don't know is whether a 3 month course of the antibiotic would have as good an effect as the studies of longer courses of antibiotics and whether the effect is sustained over the course of a year. We also would like to find out whether there are any tests which can predict whether an individual is likely to have a good or poor |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are as follows: - To evaluate whether any response to 3 months of erythromycin is sustained over 12 months. - To create phenotypes based upon inflammatory markers in blood and sputum, underlying cause and severity of the bronchiectasis, lung function and non-invasive small airway measurements while stable and during exacerbations including response to antibiotics.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Group 1 - 40 participants over 2 years including the intervention - Patients who have clinical symptoms suggestive of bronchiectasis confirmed by CT scan. - Aged 18-100. - Ability to give valid consent. - Willingness to attend the hospital every 3 months for 2 years.
Group 2 - 50 participants for baseline visit only - Patients who have clinical symptoms suggestive of bronchiectasis confirmed by CT scan. - Aged 18-100. - Ability to give valid consent. - Willingness to attend the hospital for a one off visit. |
|
E.4 | Principal exclusion criteria |
Group 1 - 40 participants over 2 years including the intervention - Active TB. - Patients under 18 and over 100. - Patients who are too unwell to attend visits. - Patients with known cystic fibrosis. - Patients with traction bronchiectasis secondary to fibrosis. - Patients who are unable to consent. - Patients already on long term antibiotics. - Patients with macrolide allergy / severe intolerance / prolonged QT interval. - Patients taking medication with a known interaction with erythromycin where the use is contraindicated, with the exception of simvastatin.
Group 2 - 50 participants for baseline visit only - Active TB. - Patients under 18 and over 100. - Patients who are too unwell to attend visits. - Patients with known cystic fibrosis. - Patients with traction bronchiectasis secondary to fibrosis. - Patients who are unable to consent.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Aim - We anticipate an improvement in the FEV1 of at least 200ml following a 3 month course of erythromycin at 250mg once a day.
Primary Hypothesis - We hypothesize that neutrophilic airway inflammation the most common phenotype in our study population and that this group will have the best response to low dose erythromycin.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The study will run for 2 years for each person. |
|
E.5.2 | Secondary end point(s) |
- To evaluate whether any response to 3 months of erythromycin is sustained over 12 months. - To create phenotypes based upon inflammatory markers in blood and sputum, underlying cause and severity of the bronchiectasis, lung function and non-invasive small airway measurements while stable and during exacerbations including response to antibiotics.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
The first 12 months of the study prior to starting the IMP. |
|
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 0 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 11 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 14 |